Recently, the Shanghai and Shenzhen Stock Exchanges released the evaluation results of information disclosure for the years 2023-2024, and Prolo Pharmaceutical (stock code: 000739) received the highest rating of A in the annual information disclosure evaluation of listed companies on the Shenzhen Stock Exchange. Prolo Pharmaceutical has won this honor for four consecutive years, fully reflecting the high recognition of the securities regulatory authorities for the company's standardized operation level, information disclosure quality, and investor relations management.The evaluation of information disclosure work on the Shenzhen Stock Exchange is a comprehensive assessment of multiple dimensions such as internal governance, information disclosure quality, investor relations management, and social responsibility fulfillment of listed companies. It is an important indicator for measuring the level of governance and information disclosure quality of listed companies. Listed companies that receive A-level evaluations can not only enhance the recognition of the capital market, but also enjoy policy support and convenience in mergers and acquisitions, refinancing reviews, and other aspects. According to statistics, a total of 5045 listed companies participated in the evaluation of information disclosure work in 2023-2024, and 912 listed companies were rated as A, accounting for 18.08%; Only 355 listed companies have been rated A for four consecutive years, accounting for 7.04%.In recent years, Prolo Pharmaceutical has always attached great importance to information disclosure work, maintaining a rigorous and cautious work style, strictly adhering to the principles of "truthfulness, accuracy, completeness, timeliness, and fairness", continuously strengthening compliance management, actively disclosing information, and fully conveying corporate value; Continuously improve communication mechanisms and respond promptly to investor concerns; Actively sharing development achievements and striving to enhance shareholder returns; Vigorously cultivate new quality productivity and continuously create greater value for investors.
In the future, Prolo Pharmaceutical will continue to practice the concept of "strong supervision, risk prevention, and promotion of high-quality development", continuously improve the quality of information disclosure, do a good job in investor relations management, strengthen the ability to serve investors, and strive to become a high-quality listed company with stable business development, public trust, and regulatory recognition.